home > ict > spring 2021 > a patient-centric approach to clinical trials
International Clinical Trials

A Patient-Centric Approach to Clinical Trials

Clinical trials are critical for the delivery of safe, new medicines to the global marketplace. This area continues to grow exponentially as new investment is injected into medical research and drug development. The clinical trials market as a whole is expected to grow at 5.7% per year to an overall value of $69.5 billion by 2028. To put this in perspective, in the year 2000, there were approximately 2,100 trials registered; by 2019, this number had grown to over 280,000 active trials.

But traditional trials are problematic for a number of reasons, leading to high costs and inefficiencies. They are logistically demanding from the onset. Recruiting volunteers and patients, and then being able to retain them, has long been a problem. With the world expected to see more infectious disease outbreaks in future, traditional trial models and practices are no longer sustainable. We need a new and innovative approach to clinical trials – one that will ensure patients have access to lifesaving treatments regardless of black swan events like the global pandemic. Luckily, the industry is coming together under these pressures to innovate and modernise.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the Author

Carolina Rossi Wosiack is Managing Director of EMEA at CI&T. Carolina is a seasoned digital executive with nearly 20 years of experience in innovative processes, people, and products, combining strategic and analytic insights and various strategy methods across design thinking and growth strategies. She has applied her expertise on a global scale across several industries in Europe, Brazil, the US, and LATAM, ranging from pharmaceuticals to consumer goods, banking, and telecommunications. Carolina has helped transform leading companies such as Roche, Sanofi, Johnson & Johnson, and Ericsson to prepare and adjust their business for rapid adaptation in the digital world.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Grupo NotreDame Intermédica (GNDI) of Brazil enhances patient care and improves patient access to leading-edge medications by joining Clinerion’s global network of hospital partners on Patient Network Explorer

Grupo NotreDame Intermédica (GNDI) is the largest healthcare operator in Brazil, with 6.4 million members. Founded in 1968, it is a pioneer in preventive medicine. GNDI has a wide offer, comprising 29 hospitals, 88 clinical centers, 23 autonomous emergency rooms, 15 preventive medicine centers and 2 health centers exclusively dedicated to the over-fifties.
More info >>

White Papers



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement